Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Oncol Rep ; 45(6)2021 06.
Article in English | MEDLINE | ID: mdl-33846807

ABSTRACT

Following the publication of the above paper, a concerned reader drew to the Editor's attention that certain of the western blotting data appeared to have been duplicated, comparing Fig. 2B with Fig. 4A; furthermore, the flow cytometric data panels featured in Fig. 3A appeared to contain repeated patternings of data within those data panels.  After having conducted an independent investigation in the Editorial Office, the Editor of Oncology Reports has determined that this paper should be retracted from the Journal on account of a lack of confidence concerning the originality and the authenticity of the data. The authors were asked for an explanation to account for these concerns, but the Editorial Office never received any reply. The Editor regrets any inconvenience that has been caused to the readership of the Journal. [the original article was published in Oncology Reports 35: 2364­2372, 2016; DOI: 10.3892/or.2016.4612].

2.
Oncol Rep ; 35(4): 2364-72, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26846469

ABSTRACT

Dracorhodin perchlorate (Dp), a synthetic analogue of the antimicrobial anthocyanin red pigment, has recently been shown to induce apoptotic cell death in various types of cancer cells. Yet, the inhibitory effect of Dp on human glioma cells remains uninvestigated. Therefore, in the present study, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry were used to detect cell viability and cell cycle progression in glioma U87MG and T98G cells, respectively. Annexin V-FITC/propidium iodide double staining and JC-1 staining were separately applied to determine cellular apoptosis and mitochondrial membrane potential damage in the cells. The expression levels of associated proteins involved in cell cycle progression and apoptosis were measured by western blotting. The activities of caspase­9/-3 were determined by Caspase-Glo-9/3 assay. The results indicated that Dp treatment significantly inhibited cell proliferation in a dose- and time-dependent manner, and blocked cell cycle progression at the G1/S phase in the U87MG and T98G cells via the upregulation of p53 and p21 protein expression, and simultaneous downregulation of Cdc25A, Cdc2 and P-Cdc2 protein expression. Additionally, Dp treatment led to the loss of cellular mitochondrial membrane potential, and the release of cytochrome c, and strongly induced the occurence of apoptosis. Increased expression levels of Bim and Bax protein and the downregulated expression of Bcl-2 protein were observed. Caspase-9/-3 were activated and their activities were elevated after Dp treatment. These findings indicate that Dp inhibits cell proliferation, induces cell cycle arrest and apoptosis in glioma cells, and is a possible candidate for glioma treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Benzopyrans/pharmacology , Brain Neoplasms/metabolism , Cell Cycle Checkpoints/drug effects , Glioma/metabolism , Apoptosis , Brain Neoplasms/drug therapy , Caspases/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Gene Expression Regulation, Neoplastic/drug effects , Glioma/drug therapy , Humans , Membrane Potential, Mitochondrial/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...